talquetamab use in treating relapsed refractory multiple myeloma | shebli atrash, md | ims 2024
Published 8 days ago • 44 plays • Length 2:44
Download video MP4
Download video MP3
Similar videos
-
1:22
talquetamab as a bridging therapy to car-t treatment | shebli atrash, md | ims 2024
-
6:18
talquetamab and teclistamab in rrmm: updated results from redirectt-1 | yael cohen, md | ims 2024
-
3:53
efficacy of reduced dosing of talquetamab in relapsed refractory myeloma | ajai chari, md | ash 2023
-
7:02
talquetamab in pts with relapsed/refractory multiple myeloma: phase 1/2 results from monumental-1
-
55:56
talquetamab side effect management
-
28:40
all about talvey (talquetamab)
-
3:15
what is the best diet for myeloma patients to build a strong immune system?
-
58:00
know your myeloma immunotherapy: teclistamab and other bispecifics
-
6:23
results of maintenance therapy in high-risk myeloma patients | ajay nooka, md, mph, facp | asco 2023
-
1:47
oral symptom assessment using pros in patients with r/r myeloma treated with talquetamab
-
43:26
relapsed/refractory multiple myeloma | detroit roundtable october 12, 2024
-
2:33
teclistamab approval for multiple myeloma treatment | ross firestone, md, phd | asco 2023
-
10:34
talquetamab - guest lecture
-
17:55
talquetamab | therapies on the horizon #myeloma
-
5:06
durability of responses with biweekly dosing of teclistamab in pts with relapsed/refractory myeloma
-
22:21
tecvayli (teclistamab) everything you need to know
-
6:59
teclistamab in combination with sub-q daratumumab and lenalidomide in myeloma pts: majestec-2
-
2:47
talquetamab daratumumab is well tolerated in relapsed/refractory multiple myeloma patients
-
4:16
what is the monoclonal antibody talvey™ (talquetamab)?
-
56:35
elranatamab: how it works, how it's being used, and how it compares to other bispecifics.
-
1:25
safety and efficacy of linvoseltamab for patients with r/r multiple myeloma
-
6:36
updated results of a phase 1, first-in-human study of talquetamab in relapsed refractory mm
Clip.africa.com - Privacy-policy